Related Experiment Videos
Thioredoxin expression in human myometrium and fibroids
1Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Hospital L5:01, S-171 76 Stockholm, Sweden.
Molecular Human Reproduction
|December 28, 1999
Summary
Thioredoxin expression in uterine fibroids and myometrium is similar and changes with endocrine status. Lower thioredoxin levels were observed in postmenopausal and GnRH agonist-treated women compared to pregnant women.
Area of Science:
- Reproductive Biology
- Molecular Endocrinology
- Oncology
Background:
- Thioredoxin is a key protein regulating DNA synthesis and metabolic processes.
- Its role in uterine fibroids and myometrium across different life stages is not fully understood.
Purpose of the Study:
- To investigate differences in thioredoxin expression between myometrium and fibroids.
- To analyze thioredoxin expression during various endocrine conditions: menstrual cycle, GnRH agonist treatment, postmenopause, and pregnancy.
Main Methods:
- Quantification of thioredoxin mRNA using solution hybridization.
- Immunohistochemical analysis of thioredoxin protein localization.
- Tissues collected from women across different reproductive and menopausal stages.
Main Results:
- Significantly lower thioredoxin mRNA levels in fibroids and myometrium from GnRH agonist-treated and postmenopausal women compared to pregnant women.
- No significant difference in thioredoxin expression between myometrium and fibroids within the same individual.
- No difference in thioredoxin expression between uteri with or without fibroids.
Conclusions:
- Uterine fibroid thioredoxin expression is not upregulated but mirrors myometrial response to endocrine changes.
- Thioredoxin expression is sensitive to hormonal fluctuations, particularly lower in postmenopausal and GnRH agonist-treated states versus pregnancy.